How Issues With Government Healthcare Cost Projections Impact GLP-1s

Article excerpt

Government healthcare cost projections have a mixed track record, yet they remain the primary tool for evaluating policies, including potential expansions of GLP-1 drug coverage. These forecasts often miss their targets by significant margins, raising questions about whether policymakers can accurately predict the fiscal impact of subsidizing weight-loss and diabetes medications. The accuracy problem matters because coverage decisions for expensive drugs like semaglutide and tirzepatide hinge largely on cost-benefit analyses rooted in these projections. Without reliable estimates, Congress and health agencies risk either overestimating savings or underestimating spending when deciding whether to expand insurance access to GLP-1s.